Thalidomide as an emerging immunotherapeutic agent.

[1]  Y. Hashimoto,et al.  Antiangiogenic activity of tumor necrosis factor-alpha production regulators derived from thalidomide. , 1999, Biological & pharmaceutical bulletin.

[2]  J. Zeldis,et al.  S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide. , 1999, Clinical therapeutics.

[3]  K. Fife,et al.  Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titre , 1998, International journal of STD & AIDS.

[4]  S. Goodbourn,et al.  CC-3052: a water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production. , 1998, Journal of immunology.

[5]  L. Corral,et al.  Thalidomide analogs and PDE4 inhibition. , 1998, Bioorganic & medicinal chemistry letters.

[6]  P. Haslett,et al.  Thalidomide Costimulates Primary Human T Lymphocytes, Preferentially Inducing Proliferation, Cytokine Production, and Cytotoxic Responses in the CD8+ Subset , 1998, The Journal of experimental medicine.

[7]  F. Kruse,et al.  Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor , 1998, Graefe's Archive for Clinical and Experimental Ophthalmology.

[8]  E. Brahn,et al.  The effect of thalidomide and 2 analogs on collagen induced arthritis. , 1998, The Journal of rheumatology.

[9]  G. Bieler,et al.  Evidence for the involvement of endotheliai cell integrin αVβ3 in the disruption of the tumor vascuiature induced by TNF and IFN-γ , 1998, Nature Medicine.

[10]  Y. Ozyazgan,et al.  Thalidomide in the Treatment of the Mucocutaneous Lesions of the Behcet Syndrome , 1998, Annals of Internal Medicine.

[11]  B. Gazzard,et al.  A double-blind placebo-controlled phase II trial of thalidomide in asymptomatic HIV-positive patients: clinical tolerance and effect on activation markers and cytokines. , 1997, AIDS research and human retroviruses.

[12]  A. Wettstein,et al.  Thalidomide in Crohn's disease , 1997, The Lancet.

[13]  G. Trinchieri,et al.  Inhibition of IL-12 production by thalidomide. , 1997, Journal of immunology.

[14]  G. Hartmann,et al.  Taming TNF: strategies to restrain this proinflammatory cytokine. , 1997, Immunology today.

[15]  A. Dalgleish,et al.  Therapeutic potential of TNF-α inhibitors old and new , 1997 .

[16]  N. Mitchison,et al.  Thalidomide therapy of established collagen‐induced arthritis (CIA) not accompanied by an evident Th2 shift , 1997, Clinical and experimental immunology.

[17]  J. Fahey,et al.  Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. , 1997, The New England journal of medicine.

[18]  C. Wilcox,et al.  A prospective trial of thalidomide for the treatment of HIV-associated idiopathic esophageal ulcers. , 1997, AIDS research and human retroviruses.

[19]  Stephan Wnendt,et al.  Thalidomide's chirality , 1997, Nature.

[20]  F. Breedveld,et al.  An open study of pentoxyfylline and thalidomide as adjuvant therapy in the treatment of rheumatoid arthritis. , 1996, Annals of the rheumatic diseases.

[21]  G. Reyes-Terán,et al.  Effects of thalidomide on HIV‐associated wasting syndrome: a randomized, double‐blind, placebo‐controlled clinical trial , 1996, AIDS.

[22]  S. Iwasaki,et al.  Cell type-/inducer-specific bidirectional regulation by thalidomide and phenylphthalimides of tumor necrosis factor-alpha production and its enantio-dependence. , 1996, Biochemical and biophysical research communications.

[23]  G. Kaplan,et al.  Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity. , 1996, Journal of medicinal chemistry.

[24]  S. Iwasaki,et al.  Augmentation by phthalimides of phorbol ester-induced expression of tumor necrosis factor alpha message. , 1996, Biological & pharmaceutical bulletin.

[25]  Gilla Kaplan,et al.  Selection of Novel Analogs of Thalidomide with Enhanced Tumor Necrosis Factor α Inhibitory Activity , 1996, Molecular medicine.

[26]  M. Pollard.  Thalidomide promotes metastasis of prostate adenocarcinoma cells (PA-III) in L-W rats. , 1996, Cancer letters.

[27]  R. Dewar,et al.  The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection. , 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[28]  B. Gazzard,et al.  The treatment of microsporidial diarrhoea with thalidomide. , 1995, AIDS.

[29]  U. Schuler,et al.  Thalidomide: Rationale for Renewed Use in Immunological Disorders , 1995, Drug safety.

[30]  C M Lockwood,et al.  The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen‐ and antigen‐stimulated human peripheral blood mononuclear cell cultures , 1995, Clinical and experimental immunology.

[31]  R. D'Amato,et al.  Thalidomide is an inhibitor of angiogenesis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[32]  G. Kaplan,et al.  The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. , 1993, The Journal of infectious diseases.

[33]  G. Kaplan,et al.  Thalidomide inhibits the replication of human immunodeficiency virus type 1. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[34]  G. Kaplan,et al.  Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation , 1993, The Journal of experimental medicine.

[35]  D. Jabs,et al.  Thalidomide for the treatment of chronic graft-versus-host disease. , 1992, The New England journal of medicine.

[36]  E. Shannon,et al.  Thalidomide's effectiveness in erythema nodosum leprosum is associated with a decrease in CD4+ cells in the peripheral blood. , 1992, Leprosy review.

[37]  G. Kaplan,et al.  Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes , 1991, The Journal of experimental medicine.

[38]  D. Noe,et al.  Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers. , 1989, Drug metabolism and disposition: the biological fate of chemicals.

[39]  D. Hawkins,et al.  Treatment of resistant aphthous ulceration with thalidomide in patients positive for HIV antibody. , 1989, BMJ.

[40]  O. Colvin,et al.  THALIDOMIDE FOR GRAFT-VERSUS-HOST DISEASE , 1988, The Lancet.

[41]  Hadler Wa,et al.  An attempt to stimulate and depress the functional activity of the inflammatory cells from lesions experimentally induced by M. leprae and M. lepraemurium. , 1965 .

[42]  G. Mellin,et al.  The saga of thalidomide. Neuropathy to embryopathy, with case reports of congenital anomalies. , 1962, The New England journal of medicine.

[43]  Taussig Hb,et al.  A study of the German outbreak of phocomelia. The thalidomide syndrome. , 1962 .

[44]  W. Mcbride,et al.  Thalidomide and Congenital Abnormalities , 1961 .

[45]  M. Kremer,et al.  Neuropathy After Intake of Thalidomide (Distaval) , 1961, British medical journal.

[46]  P. Höglund,et al.  Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide. , 1995, Chirality.

[47]  J. Languillon,et al.  WHO co-ordinated short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients. , 1971, Bulletin of the World Health Organization.